Author pages are created from data sourced from our academic publisher partnerships and public sources.
Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer.
- G. Abou-Alfa, R. Létourneau, +8 authors E. O’Reilly
- Journal of clinical oncology : official journal…
- 20 September 2006
PURPOSE Exatecan mesylate is a hexacyclic, water-soluble, topoisomerase-1 inhibitor. Exatecan has single-agent and combination activity with gemcitabine in advanced pancreatic cancer. A multicenter,… Expand
Phase II study of intravenous TZT‐1027 in patients with advanced or metastatic soft‐tissue sarcomas with prior exposure to anthracycline‐based chemotherapy
TZT‐1027, a novel chemotherapeutic agent, is derived from dolastatin 10, and blocks cells during G2/M‐phase by interfering with microtubule assembly and stability. TZT‐1027 has exhibited potential… Expand
Phase 2 study of lenvatinib (LN) in patients (Pts) with RET fusion-positive adenocarcinoma of the lung
A phase II clinical and pharmacokinetic study of intravenous exatecan mesylate (DX-8951f) in patients with untreated metastatic gastric cancer
Purpose: To determine the anti-tumor activity DX-8951f when administered as a 30-minute infusion daily for 5 days every 3 weeks to patients with previously untreated metastatic gastric cancer, and to… Expand
Phase I trial of interferon α2b and liposome‐encapsulated all‐trans retinoic acid in the treatment of patients with advanced renal cell carcinoma
Studies suggest that retinoic acid (RA) can augment the antitumor effects of interferon‐based therapy in patients with advanced renal cell carcinoma (RC); however, this benefit has not been achieved… Expand
Phase II study of eribulin mesylate (E7389) in patients with metastatic castration-resistant prostate cancer stratified by prior taxane therapy.
- J. D. de Bono, L. R. Molife, +10 authors D. Petrylak
- Annals of oncology : official journal of the…
- 1 May 2012
BACKGROUND Treatment options remain limited for patients with castration-resistant prostate cancer (CRPC). We evaluated eribulin mesylate (E7389), a nontaxane halichondrin B analog microtubule… Expand
Phase I dose-escalation study of E6201, a MEK-1 inhibitor, in advanced solid tumors.
2505 Background: E6201 is a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase (MEK)-1 and MEK kinase-1, with anticancer activity in preclinical models.… Expand
Metastatic Solid Tumors
Background: TZT-1027 is a dolastatin 10 analog interfering with microtubule assembly, with increased antitumor activity when combined with gemcitabine in animal models. Patients and Methods: Eligible… Expand
Prototype of a Microtesting System Made by the LIGA Process to Measure the Young’s Modulus in Cantilever Microbeams
A microtesting system manufactured by the LIGA process (Becker et al., 1986) combined with a new sacrificial structure technique is presented. The system is used for bending experiments to determine… Expand
A phase 2 study of TZT-1027, administered weekly to patients with advanced non-small cell lung cancer following treatment with platinum-based chemotherapy.
INTRODUCTION : TZT-1027, a derivative of dolastatin-10, has a wide spectrum of in vitro activity against cancer cell lines. We conducted a phase 2 trial of TZT-1027 in patients with previously… Expand